Product Name

  • Name

    Deferoxamine

  • EINECS 200-738-5
  • CAS No. 70-51-9
  • Article Data10
  • CAS DataBase
  • Density 1.212g/cm3
  • Solubility
  • Melting Point 139°C
  • Formula C25H48 N6 O8
  • Boiling Point 627.9°C (rough estimate)
  • Molecular Weight 560.692
  • Flash Point
  • Transport Information
  • Appearance
  • Safety Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
  • Risk Codes
  • Molecular Structure Molecular Structure of 70-51-9 (Deferoxamine)
  • Hazard Symbols
  • Synonyms Butanediamide,N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-(9CI); Propionohydroxamic acid,N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-(8CI); 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamin; Deferoxamine;Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Deferrioxamine B;Desferan; Desferex; Desferin; Desferioxamine B; Desferrin; Desferrioxamine;Desferrioxamine B;N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamicacid; NSC 527604
  • PSA 205.84000
  • LogP 2.40420

Synthetic route

C46H64N8O8

C46H64N8O8

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen; acetic acid In methanol at 25℃; under 760.051 Torr; for 0.333333h;50%
1-Carbobenzoxyamino-6,17-dihydroxy-7,10,18,21-tetraoxy-27-(N-acetyl-hydroxyamino)-6,11,17,22-tetraaza-hepteikosan
402913-84-2

1-Carbobenzoxyamino-6,17-dihydroxy-7,10,18,21-tetraoxy-27-(N-acetyl-hydroxyamino)-6,11,17,22-tetraaza-hepteikosan

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
With hydrogenchloride; hydrogen; palladium on activated charcoal In methanol
N'-<5-<<4-<<5-pentyl>amino>-1,4-dioxobutyl>(phenylmethoxy)amino>pentyl>-N-(4-cyanobutyl)-N-(phenylmethoxy)butanediamide
112139-65-8

N'-<5-<<4-<<5-pentyl>amino>-1,4-dioxobutyl>(phenylmethoxy)amino>pentyl>-N-(4-cyanobutyl)-N-(phenylmethoxy)butanediamide

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
With hydrogenchloride; hydrogen; palladium on activated charcoal In methanol
N-(5-aminopentyl)-N-(tert-butoxycarbonyl)-O-benzylhydroxylamine
129245-21-2

N-(5-aminopentyl)-N-(tert-butoxycarbonyl)-O-benzylhydroxylamine

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C
3: 96 percent / pyridine
4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
6: 91 percent / pyridine / 12 h
7: H2, HCl / 10percent Pd/C / methanol
View Scheme
5,16-bis(benzyloxy)-20-cyano-4,12,15-trioxo-5,11,16-triazaeicosanoic acid
129245-24-5

5,16-bis(benzyloxy)-20-cyano-4,12,15-trioxo-5,11,16-triazaeicosanoic acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
2: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
3: 91 percent / pyridine / 12 h
4: H2, HCl / 10percent Pd/C / methanol
View Scheme
27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile
130946-41-7

27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 91 percent / pyridine / 12 h
2: H2, HCl / 10percent Pd/C / methanol
View Scheme
27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile
130946-40-6

27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
2: 91 percent / pyridine / 12 h
3: H2, HCl / 10percent Pd/C / methanol
View Scheme
N-(4-Cyanobutyl)-N-(benzyloxy)succinamic Acid
112139-60-3

N-(4-Cyanobutyl)-N-(benzyloxy)succinamic Acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C
3: 96 percent / pyridine
4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
6: 91 percent / pyridine / 12 h
7: H2, HCl / 10percent Pd/C / methanol
View Scheme
N-(4-cyanobutyl)-3-<<5-<(benzyloxy)amino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid
129245-23-4

N-(4-cyanobutyl)-3-<<5-<(benzyloxy)amino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 96 percent / pyridine
2: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
3: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
4: 91 percent / pyridine / 12 h
5: H2, HCl / 10percent Pd/C / methanol
View Scheme
N-(4-cyanobutyl)-3-<<5-<(benzyloxy)-tert-butoxy-carbonylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid
129245-22-3

N-(4-cyanobutyl)-3-<<5-<(benzyloxy)-tert-butoxy-carbonylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C
2: 96 percent / pyridine
3: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
4: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
5: 91 percent / pyridine / 12 h
6: H2, HCl / 10percent Pd/C / methanol
View Scheme
1-(Carbobenzoxyamino)-5-(hydroxyamino)pentane
91905-05-4

1-(Carbobenzoxyamino)-5-(hydroxyamino)pentane

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: Py
2: acetic anhydride / 5 h / 95 - 100 °C
3: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
4: H2, aq. HCl / Pd-C / methanol
View Scheme
Multi-step reaction with 6 steps
1: Py
2: acetic anhydride / 5 h / 95 - 100 °C
3: (i) NaOMe, MeOH, (ii) /BRN= 898057/, THF
4: (i) aq. NH4Cl, Zn, EtOH, (ii) /BRN= 385737/, Py
5: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
6: H2, aq. HCl / Pd-C / methanol
View Scheme
1-Carbobenzoxyamino-5-nitro-pentan
92034-20-3

1-Carbobenzoxyamino-5-nitro-pentan

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: aq. NH4Cl, Zn / ethanol
2: Py
3: acetic anhydride / 5 h / 95 - 100 °C
4: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
5: H2, aq. HCl / Pd-C / methanol
View Scheme
Multi-step reaction with 7 steps
1: aq. NH4Cl, Zn / ethanol
2: Py
3: acetic anhydride / 5 h / 95 - 100 °C
4: (i) NaOMe, MeOH, (ii) /BRN= 898057/, THF
5: (i) aq. NH4Cl, Zn, EtOH, (ii) /BRN= 385737/, Py
6: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
7: H2, aq. HCl / Pd-C / methanol
View Scheme
N-(5-benzyloxycarbonylamino-pentyl)-N-hydroxy-succinamic acid
106410-46-2

N-(5-benzyloxycarbonylamino-pentyl)-N-hydroxy-succinamic acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: acetic anhydride / 5 h / 95 - 100 °C
2: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
3: H2, aq. HCl / Pd-C / methanol
View Scheme
Multi-step reaction with 5 steps
1: acetic anhydride / 5 h / 95 - 100 °C
2: (i) NaOMe, MeOH, (ii) /BRN= 898057/, THF
3: (i) aq. NH4Cl, Zn, EtOH, (ii) /BRN= 385737/, Py
4: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
5: H2, aq. HCl / Pd-C / methanol
View Scheme
1-Carbobenzoxyamino-6-hydroxy-16-nitro-7,10-dioxo-6,11-diaza-hexadecan
95228-06-1

1-Carbobenzoxyamino-6-hydroxy-16-nitro-7,10-dioxo-6,11-diaza-hexadecan

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: (i) aq. NH4Cl, Zn, EtOH, (ii) /BRN= 385737/, Py
2: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
3: H2, aq. HCl / Pd-C / methanol
View Scheme
N(1)-Benzyloxycarbonyl-6,17-dihydroxy-7,10,18-trioxo-6,11,17-triazanonadecylamin
95748-46-2

N(1)-Benzyloxycarbonyl-6,17-dihydroxy-7,10,18-trioxo-6,11,17-triazanonadecylamin

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
2: H2, aq. HCl / Pd-C / methanol
View Scheme
5-nitropentylammonium chloride

5-nitropentylammonium chloride

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: aq. NaOH
2: aq. NH4Cl, Zn / ethanol
3: Py
4: acetic anhydride / 5 h / 95 - 100 °C
5: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
6: H2, aq. HCl / Pd-C / methanol
View Scheme
Multi-step reaction with 8 steps
1: aq. NaOH
2: aq. NH4Cl, Zn / ethanol
3: Py
4: acetic anhydride / 5 h / 95 - 100 °C
5: (i) NaOMe, MeOH, (ii) /BRN= 898057/, THF
6: (i) aq. NH4Cl, Zn, EtOH, (ii) /BRN= 385737/, Py
7: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
8: H2, aq. HCl / Pd-C / methanol
View Scheme
[5-(3,6-dioxo-[1,2]oxazinan-2-yl)-pentyl]-carbamic acid benzyl ester
94622-86-3

[5-(3,6-dioxo-[1,2]oxazinan-2-yl)-pentyl]-carbamic acid benzyl ester

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
2: H2, aq. HCl / Pd-C / methanol
View Scheme
Multi-step reaction with 4 steps
1: (i) NaOMe, MeOH, (ii) /BRN= 898057/, THF
2: (i) aq. NH4Cl, Zn, EtOH, (ii) /BRN= 385737/, Py
3: (i) H2, Pd-C, MeOH, (ii) /BRN= 898057/
4: H2, aq. HCl / Pd-C / methanol
View Scheme
N-acetyl-N-hydroxy-1,5-diaminopentane
144108-69-0

N-acetyl-N-hydroxy-1,5-diaminopentane

4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoic acid

4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoic acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
With DesD Enzymatic reaction;
1,5-dibromo-pentane
111-24-0

1,5-dibromo-pentane

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: sodium hydride / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere
2: sodium azide / N,N-dimethyl-formamide / 3 h / 80 °C
3: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
4: pyridine / 100 °C
5: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
6: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 8 steps
1.1: sodium hydride / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere
2.1: sodium azide / N,N-dimethyl-formamide / 3 h / 80 °C
3.1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
4.1: pyridine / 100 °C
5.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
6.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
6.2: 1 h / 80 °C
7.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
8.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 9 steps
1.1: sodium hydride / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere
2.1: sodium azide / N,N-dimethyl-formamide / 3 h / 80 °C
3.1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
4.1: dmap / dichloromethane / 0.25 h / 0 - 20 °C
5.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
5.2: 1 h / 80 °C
6.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
7.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
7.2: 1 h / 80 °C
8.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
9.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
1-Amino-5-pentane
83966-23-8

1-Amino-5-pentane

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
2.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
2.2: 1 h / 80 °C
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
4.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
tert-butyl(benzyloxy)(5-bromopentyl)carbamate

tert-butyl(benzyloxy)(5-bromopentyl)carbamate

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: sodium azide / N,N-dimethyl-formamide / 3 h / 80 °C
2: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
3: pyridine / 100 °C
4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
5: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 7 steps
1.1: sodium azide / N,N-dimethyl-formamide / 3 h / 80 °C
2.1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
3.1: pyridine / 100 °C
4.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
5.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
5.2: 1 h / 80 °C
6.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
7.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 8 steps
1.1: sodium azide / N,N-dimethyl-formamide / 3 h / 80 °C
2.1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
3.1: dmap / dichloromethane / 0.25 h / 0 - 20 °C
4.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
4.2: 1 h / 80 °C
5.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
6.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
6.2: 1 h / 80 °C
7.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
8.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
t-butyl(5-azidopentyl)(benzyloxy)carbamate

t-butyl(5-azidopentyl)(benzyloxy)carbamate

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
2: pyridine / 100 °C
3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
4: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 6 steps
1.1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
2.1: pyridine / 100 °C
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
4.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
4.2: 1 h / 80 °C
5.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
6.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 7 steps
1.1: trifluoroacetic acid / dichloromethane / 0.33 h / 0 - 20 °C
2.1: dmap / dichloromethane / 0.25 h / 0 - 20 °C
3.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
3.2: 1 h / 80 °C
4.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
5.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
5.2: 1 h / 80 °C
6.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
7.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
C14H20N4O2

C14H20N4O2

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
1.2: 1 h / 80 °C
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
3.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
3.2: 1 h / 80 °C
4.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
5.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
C30H42N6O5

C30H42N6O5

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
1.2: 1 h / 80 °C
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
3.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
C16H22N4O4

C16H22N4O4

N-(5-aminopentyl)-3-<<5-<(benzyloxy)acetylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid
112139-64-7

N-(5-aminopentyl)-3-<<5-<(benzyloxy)acetylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
2: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
N-(5-azidopentyl)-O-benzylhydroxylamine

N-(5-azidopentyl)-O-benzylhydroxylamine

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: pyridine / 100 °C
2: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
3: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 5 steps
1.1: pyridine / 100 °C
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
3.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
3.2: 1 h / 80 °C
4.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
5.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
Multi-step reaction with 6 steps
1.1: dmap / dichloromethane / 0.25 h / 0 - 20 °C
2.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
2.2: 1 h / 80 °C
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
4.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
4.2: 1 h / 80 °C
5.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
6.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
C16H22N4O4

C16H22N4O4

deferoxamine
70-51-9

deferoxamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 3 h / 25 °C / Inert atmosphere
2.1: triphenylphosphine / tetrahydrofuran / 1 h / 80 °C
2.2: 1 h / 80 °C
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap / dichloromethane / 25 °C / Inert atmosphere
4.1: acetic acid; palladium 10% on activated carbon; hydrogen / methanol / 0.33 h / 25 °C / 760.05 Torr
View Scheme
deferoxamine
70-51-9

deferoxamine

water
7732-18-5

water

zirconium(IV) chloride
10026-11-6

zirconium(IV) chloride

zirconium(IV) desferrioxamine(OH)2

zirconium(IV) desferrioxamine(OH)2

Conditions
ConditionsYield
at 20℃; for 24h;100%
...Expand
deferoxamine
70-51-9

deferoxamine

formic acid ethyl ester
109-94-4

formic acid ethyl ester

formamide deferoxamine

formamide deferoxamine

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide for 15h; Heating;90%
1 ,4-phenylenediisothiocyanate
4044-65-9

1 ,4-phenylenediisothiocyanate

deferoxamine
70-51-9

deferoxamine

N-[5-({3-[5-(acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-hydroxy-N'-{5-[3-(4-isothiocyanato-phenyl)-thioureido]-pentyl}-succinamide
1222468-90-7

N-[5-({3-[5-(acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-hydroxy-N'-{5-[3-(4-isothiocyanato-phenyl)-thioureido]-pentyl}-succinamide

Conditions
ConditionsYield
With triethylamine In chloroform; water; isopropyl alcohol at 20℃; for 1.5h;89%
deferoxamine
70-51-9

deferoxamine

3,4-dimethoxy-3-cyclobutene-1,2-dione
5222-73-1

3,4-dimethoxy-3-cyclobutene-1,2-dione

C30H50N6O11
1300025-15-3

C30H50N6O11

Conditions
ConditionsYield
With triethylamine In methanol at 23℃; for 6h; Inert atmosphere;88%
3-(4-nitrophenyl)-1-adamantanecarboxylic acid
7123-76-4

3-(4-nitrophenyl)-1-adamantanecarboxylic acid

deferoxamine
70-51-9

deferoxamine

C42H65N7O11

C42H65N7O11

Conditions
ConditionsYield
Stage #1: 3-(4-nitrophenyl)-1-adamantanecarboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		71%
deferoxamine
70-51-9

deferoxamine

4-pentylbicyclo[2.2.2]octane-1-carboxylic acid

4-pentylbicyclo[2.2.2]octane-1-carboxylic acid

C39H70N6O9

C39H70N6O9

Conditions
ConditionsYield
Stage #1: 4-pentylbicyclo[2.2.2]octane-1-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		66%
deferoxamine
70-51-9

deferoxamine

C22H23NO7

C22H23NO7

C47H69N7O14

C47H69N7O14

Conditions
ConditionsYield
Stage #1: C22H23NO7 With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate In N,N-dimethyl-formamide for 0.166667h; Cooling with ice;
Stage #2: deferoxamine With 4-methyl-morpholine; potassium hydroxide In water; N,N-dimethyl-formamide at 20℃; for 96h;		58%
3-bromoadamantane-1-carboxylic acid
21816-08-0

3-bromoadamantane-1-carboxylic acid

deferoxamine
70-51-9

deferoxamine

C36H61BrN6O9

C36H61BrN6O9

Conditions
ConditionsYield
Stage #1: 3-bromoadamantane-1-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		52%
1-chloro-3-adamantanecarboxylic acid
34859-74-0

1-chloro-3-adamantanecarboxylic acid

deferoxamine
70-51-9

deferoxamine

C36H61ClN6O9

C36H61ClN6O9

Conditions
ConditionsYield
Stage #1: 3-chloroadamantane-1-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		47%
deferoxamine
70-51-9

deferoxamine

C17H23NO4

C17H23NO4

N1-(5-((1r,3R,5S,7r)-3,5-dimethyladamantane-1-carboxamido)pentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide

N1-(5-((1r,3R,5S,7r)-3,5-dimethyladamantane-1-carboxamido)pentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide

Conditions
ConditionsYield
With sodium hydroxide In methanol at 70℃; for 3h;44%
(3-bromo-1-adamantyl)acetic acid
17768-34-2

(3-bromo-1-adamantyl)acetic acid

deferoxamine
70-51-9

deferoxamine

C37H63BrN6O9

C37H63BrN6O9

Conditions
ConditionsYield
Stage #1: (3-bromo-1-adamantyl)acetic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		35%
deferoxamine
70-51-9

deferoxamine

2-(3-hydroxyadamantan-1-yl)acetic acid
17768-36-4

2-(3-hydroxyadamantan-1-yl)acetic acid

C37H64N6O10

C37H64N6O10

Conditions
ConditionsYield
Stage #1: (3-hydroxyadamantan-1-yl)acetic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		34%
3,5-dimethyladamantane-1-acetic acid
14202-14-3

3,5-dimethyladamantane-1-acetic acid

deferoxamine
70-51-9

deferoxamine

C39H68N6O9

C39H68N6O9

Conditions
ConditionsYield
Stage #1: acide dimethyl-3,5 adamantylacetique With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		28%
3,5,7-trimethyladamantanecarboxylic acid
15291-66-4

3,5,7-trimethyladamantanecarboxylic acid

deferoxamine
70-51-9

deferoxamine

C39H68N6O9

C39H68N6O9

Conditions
ConditionsYield
Stage #1: 3,5,7-trimethyladamantanecarboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		27%
3,5-dimethyl-1-adamantanecarboxylic acid
14670-94-1

3,5-dimethyl-1-adamantanecarboxylic acid

deferoxamine
70-51-9

deferoxamine

DFOB-AdAdMe
1149568-52-4

DFOB-AdAdMe

Conditions
ConditionsYield
Stage #1: 3,5-dimethyl-1-adamantanecarboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		24%
1-Adamantanecarboxylic acid
828-51-3

1-Adamantanecarboxylic acid

deferoxamine
70-51-9

deferoxamine

DFOB-AdA
1150314-06-9

DFOB-AdA

Conditions
ConditionsYield
Stage #1: 1-Adamantanecarboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		22%
deferoxamine
70-51-9

deferoxamine

2-((2'-((((2'',5''-dioxopyrrolidin-1''-yl)oxy)carbonyl)oxy)ethyl)disulfanyl)ethyl (2'''-butyl-1''',3'''-dioxo-2''',3'''-dihydro-1H-benzo[de]isoquinolin-6'''-yl)carbamate

2-((2'-((((2'',5''-dioxopyrrolidin-1''-yl)oxy)carbonyl)oxy)ethyl)disulfanyl)ethyl (2'''-butyl-1''',3'''-dioxo-2''',3'''-dihydro-1H-benzo[de]isoquinolin-6'''-yl)carbamate

C47H70N8O14S2

C47H70N8O14S2

Conditions
ConditionsYield
In tetrahydrofuran; aq. phosphate buffer at 20℃; for 14h; pH=8; Inert atmosphere;21%
deferoxamine
70-51-9

deferoxamine

Cyclohexanecarboxylic acid
98-89-5

Cyclohexanecarboxylic acid

C32H58N6O9

C32H58N6O9

Conditions
ConditionsYield
Stage #1: Cyclohexanecarboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		21%
deferoxamine
70-51-9

deferoxamine

methanesulfonyl chloride
124-63-0

methanesulfonyl chloride

methylsulfonamide deferoxamine

methylsulfonamide deferoxamine

Conditions
ConditionsYield
With iron(III) chloride In chloroform for 0.5h; pH=8.5;20%
3-noradamantanecarboxylic acid
16200-53-6

3-noradamantanecarboxylic acid

deferoxamine
70-51-9

deferoxamine

C35H60N6O9

C35H60N6O9

Conditions
ConditionsYield
Stage #1: 3-noradamantanecarboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		19%
endo-bicyclo<3,3,1>nonan-3-carboxylic acid
6221-62-1

endo-bicyclo<3,3,1>nonan-3-carboxylic acid

deferoxamine
70-51-9

deferoxamine

C35H62N6O9

C35H62N6O9

Conditions
ConditionsYield
Stage #1: endo-bicyclo<3,3,1>nonan-3-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		17%
deferoxamine
70-51-9

deferoxamine

(+)-(1R,4R,5S)-bicyclo<2.2.1>hept-2-ene-5-carboxylic acid
120-74-1, 934-30-5, 1195-12-6, 20507-53-3, 58001-99-3, 67999-50-2, 74645-32-2, 108266-75-7, 67999-53-5

(+)-(1R,4R,5S)-bicyclo<2.2.1>hept-2-ene-5-carboxylic acid

C33H56N6O9

C33H56N6O9

Conditions
ConditionsYield
Stage #1: (+)-(1R,4R,5S)-bicyclo<2.2.1>hept-2-ene-5-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		17%
deferoxamine
70-51-9

deferoxamine

C16H26N4O8

C16H26N4O8

N’-(1-azido-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl)-N1-hydroxy-N”-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)-succinamide

N’-(1-azido-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl)-N1-hydroxy-N”-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)-succinamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 40 - 45℃; for 7h; Inert atmosphere;15%
deferoxamine
70-51-9

deferoxamine

11-hydroxy-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazapentadecan-15-oic acid

11-hydroxy-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazapentadecan-15-oic acid

N1-(1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-3-oxa-6,11,17,22-tetraazaheptacosan-27-yl)-N1-hydroxy-N4-(5-(N-hydroxyacetamido)pentyl)succinamide

N1-(1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-3-oxa-6,11,17,22-tetraazaheptacosan-27-yl)-N1-hydroxy-N4-(5-(N-hydroxyacetamido)pentyl)succinamide

Conditions
ConditionsYield
Stage #1: 11-hydroxy-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazapentadecan-15-oic acid With di(succinimido) carbonate; triethylamine In N,N-dimethyl-formamide for 4h; Inert atmosphere;
Stage #2: deferoxamine In N,N-dimethyl-formamide Inert atmosphere;
Stage #3: With trifluoroacetic acid In dichloromethane for 2h; Inert atmosphere;		12%
deferoxamine
70-51-9

deferoxamine

(1R,4R)-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid

(1R,4R)-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid

C33H56N6O9

C33H56N6O9

Conditions
ConditionsYield
Stage #1: (1R,4R)-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		11%
di(succinimido) carbonate
74124-79-1

di(succinimido) carbonate

deferoxamine
70-51-9

deferoxamine

methyl (1S,4E,6R)-6-{[(4-{[(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethyl)carbamoyl] (hydroxy)methyl}phenyl)(methyl)carbamoyl]oxy}-1-hydroxycyclooct-4-ene-1-carboxylate

methyl (1S,4E,6R)-6-{[(4-{[(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethyl)carbamoyl] (hydroxy)methyl}phenyl)(methyl)carbamoyl]oxy}-1-hydroxycyclooct-4-ene-1-carboxylate

TCO-mandelic-(PEG2-Mal)-DFO

TCO-mandelic-(PEG2-Mal)-DFO

Conditions
ConditionsYield
Stage #1: di(succinimido) carbonate; methyl (1S,4E,6R)-6-{[(4-{[(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethyl)carbamoyl] (hydroxy)methyl}phenyl)(methyl)carbamoyl]oxy}-1-hydroxycyclooct-4-ene-1-carboxylate With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 20℃; for 96h;
Stage #2: deferoxamine In dimethyl sulfoxide at 20℃; for 1h;		11%
...Expand
deferoxamine
70-51-9

deferoxamine

bicyclo<2.2.1>heptane-2-carboxylic acid
870708-34-2

bicyclo<2.2.1>heptane-2-carboxylic acid

C33H58N6O9

C33H58N6O9

Conditions
ConditionsYield
Stage #1: bicyclo<2.2.1>heptane-2-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		8%
deferoxamine
70-51-9

deferoxamine

2-((1S,4R)-bicyclo[2.2.1]heptan-2-yl)acetic acid

2-((1S,4R)-bicyclo[2.2.1]heptan-2-yl)acetic acid

C34H60N6O9

C34H60N6O9

Conditions
ConditionsYield
Stage #1: 2-((1S,4R)-bicyclo[2.2.1]heptan-2-yl)acetic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 24h; Inert atmosphere;
Stage #2: deferoxamine With sodium hydroxide In methanol at 70℃; for 3h; Inert atmosphere;		8%

Deferoxamine Chemical Properties

Molecular Formula: C25H48N6O8
Molar mass: 560.684 g/mol
EINECS: 200-738-5
Density: 1.212 g/cm3
Index of Refraction: 1.537
Structure of Deferoxamine (CAS NO.70-51-9):
               

Deferoxamine Uses

  Deferoxamine (CAS NO.70-51-9) is used to treat acute iron poisoning, especially in small children and is also frequently used to treat hemochromatosis, a disease of iron accumulation that can be either genetic or acquired. Another, it has also been used in the treatment of a patient with aceruloplasminemia.

Deferoxamine Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo multiple routes 440mg/kg/6D-I (440mg/kg) SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE" Archives of Disease in Childhood. Vol. 63, Pg. 250, 1988.
child TDLo subcutaneous 12gm/kg/17W-I (12000mg/kg) SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE
SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR		 New England Journal of Medicine. Vol. 314, Pg. 869, 1986.
human TDLo subcutaneous 37gm/kg/2Y-I (37000mg/kg) SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE New England Journal of Medicine. Vol. 314, Pg. 869, 1986.
man TDLo intravenous 86mg/kg/1H-C (86mg/kg) BLOOD: THROMBOCYTOPENIA American Journal of Kidney Diseases. Vol. 6, Pg. 254, 1985.
mouse LD50 intraperitoneal 1680mg/kg (1680mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 99, 1970.
mouse LD50 intravenous 250mg/kg (250mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA United States Patent Document. Vol. #4863964,
mouse LD50 oral 1340mg/kg (1340mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 748, 1967.
mouse LD50 subcutaneous 1450mg/kg (1450mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975.
rat LD50 intravenous 329mg/kg (329mg/kg)   Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
rat LD50 subcutaneous 12240mg/kg (12240mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975.
women TDLo intravenous 40mg/kg (40mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE
SENSE ORGANS AND SPECIAL SENSES: HEMORRHAGE: EYE		 Nephron. Vol. 46, Pg. 211, 1987.
 

Deferoxamine Safety Profile

Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

Deferoxamine Specification

 Deferoxamine ,its cas register number is 70-51-9. It also can be called Desferrioxamine B ; Desferoxamine B ; DFO-B ; DFOA ; DFB or Desferal . It acts by binding free iron in the bloodstream and enhancing its elimination in the urine. Deferoxamine (CAS NO.70-51-9) may modulate expression and release of inflammatory mediators by specific cell types. A recent study shows that it speeds healing of nerve damage. Its administration after acute intoxication may color the urine a pinkish red, a phenomenon termed "vin rose urine".

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View